Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference
06 August 2020 - 10:00PM
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage
biopharmaceutical company aimed at developing and commercializing
therapies for the treatment of rare genetic disorders of obesity,
today announced that David Meeker, M.D., Chair, President and Chief
Executive Officer of Rhythm, and Hunter Smith, Chief Financial
Officer, will present a corporate overview at the Canaccord Genuity
40th Annual Growth Conference on Thursday, August 13, 2020 at 9:30
a.m. ET.
A live audio webcast of the presentation will be available under
“Events & Presentations” in the Investor Relations section of
the Company’s website at www.rhythmtx.com. A replay of the webcast
will be available on the Rhythm website for 30 days following each
presentation.
About Rhythm PharmaceuticalsRhythm is a
late-stage biopharmaceutical company focused on the development and
commercialization of therapies for the treatment of rare genetic
disorders of obesity. The Company is developing setmelanotide, its
investigational, melanocortin-4 receptor (MC4R) agonist, for the
treatment of severe obesity and hyperphagia associated with rare
genetic disorders of obesity. The U.S. Food and Drug Administration
(FDA) has accepted for filing Rhythm’s New Drug Application (NDA)
for setmelanotide for the treatment of pro-opiomelanocortin (POMC)
deficiency obesity and leptin receptor (LEPR) deficiency obesity
with Priority Review and a Prescription Drug User Fee Act (PDUFA)
goal date of November 27, 2020. Rhythm also submitted a
Marketing Authorization Application (MAA) for setmelanotide to
treat individuals living with POMC deficiency obesity or LEPR
deficiency obesity to the European Medicines Agency (EMA)
in June 2020. Rhythm is also evaluating setmelanotide for
reduction in hunger and body weight in a pivotal Phase 3 trial in
people living with Bardet-Biedl and Alström syndromes, with topline
data from this trial expected in the fourth quarter of 2020 or
early in the first quarter of 2021. Rhythm is leveraging the Rhythm
Engine -- comprised of its Phase 2 basket study, TEMPO Registry,
GO-ID genotyping study and Uncovering Rare Obesity program -- to
improve the understanding, diagnosis and potentially the treatment
of rare genetic disorders of obesity. For healthcare professionals,
visit www.UNcommonObesity.com for more information. For
patients and caregivers, visit www.LEADforRareObesity.com for
more information. The company is based in Boston, MA.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including without limitation statements regarding the
potential, safety, efficacy, and regulatory and clinical progress
of setmelanotide, expectations regarding regulatory approval, the
anticipated timing for release of clinical trial data, and
participation in upcoming presentations and conferences. Statements
using words such as “expect”, “anticipate”, “believe”, “may”,
“will” and similar terms are also forward-looking statements.
These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to
be materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the impact of our
management transition, our ability to enroll patients in clinical
trials, the design and outcome of clinical trials, the impact of
competition, the ability to achieve or obtain necessary regulatory
approvals, risks associated with data analysis and reporting, our
liquidity and expenses, the impact of the COVID-19 pandemic on our
business and operations, including our preclinical studies,
clinical trials and commercialization prospects, and general
economic conditions, and other important factors discussed under
the caption “Risk Factors” in our Quarterly Report on Form 10-Q for
the quarterly period ended June 30, 2020 and our other
filings with the Securities and Exchange Commission. Except as
required by law, we undertake no obligations to make any revisions
to the forward-looking statements contained in this release or to
update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information,
future developments or otherwise.
Corporate Contact:David ConnollyHead of
Investor Relations and Corporate CommunicationsRhythm
Pharmaceuticals, Inc.857-264-4280dconnolly@rhythmtx.com
Investor Contact:Hannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact:Adam DaleyBerry & Company
Public Relations212-253-8881adaley@berrypr.com
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From Apr 2024 to May 2024
Rhythm Pharmaceuticals (NASDAQ:RYTM)
Historical Stock Chart
From May 2023 to May 2024